
Abcuro Reports Phase 2/3 MUSCLE Study Results of Ulviprubart in Inclusion Body Myositis at GCOM 2026
Abcuro Highlights Phase 2/3 MUSCLE Study Results of Ulviprubart in Inclusion Body Myositis at GCOM 2026 Abcuro, Inc. has announced new clinical data from its Phase 2/3 MUSCLE study evaluating…












